Nebula Research & Development’s Bausch Health BHC Stock Holding History

Nebula Research & Development’s Portfolio BHC Stock Details BHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-37,424	Closed	-$249K	–	115
2025 Q2	$249K	Buy	37,424 +13,623	+57%	+$70K	0.02%	834
2025 Q1	$154K	Sell	23,801 -9,223	-28%	-$66.3K	0.01%	887
2024 Q4	$266K	Sell	33,024 -23,076	-41%	-$190K	0.03%	738
2024 Q3	$458K	Sell	56,100 -88,732	-61%	-$585K	0.05%	578
2024 Q2	$1.01M	Buy	+144,832	New	+$1.1M	0.16%	217
2024 Q1	–	Sell	-19,289	Closed	-$155K	–	747
2023 Q4	$155K	Sell	19,289 -32,939	-63%	-$240K	0.05%	576
2023 Q3	$429K	Sell	52,228 -25,964	-33%	-$224K	0.23%	166
2023 Q2	$626K	Buy	78,192 +64,650	+477%	+$477K	0.47%	69
2023 Q1	$110K	Buy	+13,542	New	+$109K	0.19%	200

Other funds holding BHC

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nebula Research & Development's BHC Position: Q3 2025 in Review

Nebula Research & Development sold out of Bausch Health (BHC) in Q3 2025, closing a stake of 37,424 shares — an estimated $249K sold.

Nebula Research & Development first reported a position in BHC in Q1 2023 and held it in 9 quarters. The position peaked at $1.01M in Q2 2024. 219 funds tracked by Wall St. Rank hold BHC as of Q3 2025.

Nebula Research & Development reported no remaining Bausch Health position as of Q3 2025 after selling out during the quarter.
Nebula Research & Development sold 37,424 Bausch Health shares in Q3 2025, an estimated $249K.
Nebula Research & Development first reported a position in Bausch Health in Q1 2023 and held it in 9 quarters.
Nebula Research & Development's Bausch Health position peaked at $1.01M in Q2 2024.
219 funds tracked by Wall St. Rank held Bausch Health as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.